Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

SOPH SOPHiA Genetics SA

Price (delayed)

$3

Market cap

$200.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

$162.07M

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and ...

Highlights
SOPH's gross profit is up by 4.9% year-on-year and by 4.1% since the previous quarter
SOPHiA Genetics's revenue has increased by 4.7% YoY and by 3.1% QoQ
SOPHiA Genetics's EPS has increased by 11% YoY but it has decreased by 5% from the previous quarter
The net income has grown by 9% YoY but it has contracted by 6% from the previous quarter
SOPHiA Genetics's debt has surged by 73% YoY
SOPH's equity is down by 35% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of SOPH
Market
Shares outstanding
66.82M
Market cap
$200.46M
Enterprise value
$162.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.34
Price to sales (P/S)
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.41
Earnings
Revenue
$67.17M
Gross profit
$45.74M
Operating income
-$63.85M
Net income
-$66.17M
EBIT
-$63.42M
EBITDA
-$54.59M
Free cash flow
-$40.19M
Per share
EPS
-$1
EPS diluted
-$1
Free cash flow per share
-$0.6
Book value per share
$1.28
Revenue per share
$1.01
TBVPS
$1.75
Balance sheet
Total assets
$146.72M
Total liabilities
$61.11M
Debt
$30.13M
Equity
$85.61M
Working capital
$61.11M
Liquidity
Debt to equity
0.35
Current ratio
3.11
Quick ratio
2.74
Net debt/EBITDA
0.7
Margins
EBITDA margin
-81.3%
Gross margin
68.1%
Net margin
-98.5%
Operating margin
-95.1%
Efficiency
Return on assets
-40.1%
Return on equity
-63.5%
Return on invested capital
-126.4%
Return on capital employed
-53.9%
Return on sales
-94.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SOPH stock price

How has the SOPHiA Genetics stock price performed over time
Intraday
-0.83%
1 week
4.53%
1 month
-0.99%
1 year
-40%
YTD
-2.28%
QTD
-9.64%

Financial performance

How have SOPHiA Genetics's revenue and profit performed over time
Revenue
$67.17M
Gross profit
$45.74M
Operating income
-$63.85M
Net income
-$66.17M
Gross margin
68.1%
Net margin
-98.5%
The operating margin has grown by 18% YoY and by 7% from the previous quarter
SOPH's operating income is up by 14% YoY and by 4.1% from the previous quarter
SOPHiA Genetics's net margin has increased by 13% YoY but it has decreased by 2.7% QoQ
The net income has grown by 9% YoY but it has contracted by 6% from the previous quarter

Price vs fundamentals

How does SOPH's price correlate with its fundamentals

Growth

What is SOPHiA Genetics's growth rate over time

Valuation

What is SOPHiA Genetics stock price valuation
P/E
N/A
P/B
2.34
P/S
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.41
SOPHiA Genetics's EPS has increased by 11% YoY but it has decreased by 5% from the previous quarter
SOPH's equity is down by 35% year-on-year and by 11% since the previous quarter
The P/S is 19% below the last 4 quarters average of 3.7
SOPHiA Genetics's revenue has increased by 4.7% YoY and by 3.1% QoQ

Efficiency

How efficient is SOPHiA Genetics business performance
SOPHiA Genetics's ROE has decreased by 33% YoY and by 18% from the previous quarter
The ROIC has grown by 32% YoY
SOPHiA Genetics's ROS has increased by 16% YoY but it has decreased by 3.6% from the previous quarter
The ROA has declined by 12% year-on-year and by 11% since the previous quarter

Dividends

What is SOPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SOPH.

Financial health

How did SOPHiA Genetics financials performed over time
SOPH's total assets is 140% greater than its total liabilities
The company's quick ratio fell by 28% YoY and by 16% QoQ
The total liabilities has grown by 27% YoY and by 3.9% from the previous quarter
SOPHiA Genetics's debt is 65% lower than its equity
The debt to equity has soared by 169% year-on-year and by 13% since the previous quarter
SOPHiA Genetics's debt has surged by 73% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.